Conformis Completes Executive Team With Addition of CFO
Burlington, Mass. – May 5, 2008 – Conformis, Inc., a privately held company that develops and commercializes minimally invasive medical devices for the treatment of osteoarthritis and joint damage, today announced the appointment of Ms. Judith Huber to Chief Financial Officer. The addition fully rounds out the executive team, which includes recently named Chairman Phil ipp Lang, MD, as Chief Executive Officer and Phil Licari as Chief Operating Officer.
Ms. Huber brings more than 20 years of financial experience, predominately in the medical device industry, to Conformis. Most recently, Ms. Huber served as Vice President and Controller at NxStage Medical where she was instrumental in building the financial and administrative infrastructure that led to the companyâ€™s initial public offering, secondary financing and acquisition of Medisystems Corporation.
“We are extremely pleased to welcome Judy as the final member of the Conformis executive team,” said Chairman and CEO Philipp Lang, MD. “Judy joins Conformis at an exciting time in our company’s history as we’ve seen demand across the globe for our line of patient-specific implants increase substantially. Her experience in building financial infrastructure to support growth on both the operations and commercialization fronts will play a key role as we head into the second half of 2008 and beyond.”
Prior to joining NxStage Medical, Ms. Huber spent more than nine years in various financial positions with C. R. Bard and AVE/Medtronic. She supported multiple divisions focused on improving the economic efficiencies of their manufacturing operations.
“I’m looking forward to working with an accomplished team of executives at such an important and exciting time in Conformis’ growth,” said Ms. Huber. “Delivering on the opportunity to build a robust financial capability for Conformis will enable the company to continue on the path to becoming a major player in the orthopedic market.”
Ms. Huber earned a B.S. in Accounting from the State University of New York at Geneseo and an M.B.A. from the Babson College . She is also a Certified Management Accountant.
About Conformis, Inc.
Conformis, Inc. is a privately held company incorporated in 2004 that develops and commercializes medical devices for the treatment of osteoarthritis and joint damages. The Company’s novel and scaleable ‘image-to-implant’ process is comprised of two related technology platforms. iFit™ Technology enables the creation of conforming, patient-specific implants that are precisely sized and shaped to match the 3D topography of the patient’s bone surfaces. The iJig™ Instrumentation enables the creation of novel, disposable cutting and placement guides that simplify and improve the surgical process.
Both platforms are supported by proprietary, intellectual property consisting of more than 120 issued patents or pending patent applications that span imaging software, image processing, implant design, surgical techniques and instrumentation.
To date, Conformis has developed a comprehensive line of minimally traumatic, bone and cartilage-preserving knee implants and instrumentation designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery. Each device has been cleared by the US Food and Drug Administration for marketing in the U.S.
Conformis, Inc. Announces 510(k) Clearance for Identity Imprint™ Knee Replacement System
Leveraging Conformis’ extensive library of personalized knee design data and patient images, Identity Imprint is designed to match patients’ anatomy
Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants
Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable